Fineline Cube

Follow:
14691 Articles
China's NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products
Policy / Regulatory

China’s NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products

Merck Licenses SciBrunch's Oral KRAS G12D Inhibitor SPR2015 in Up to USD 2.13 Billion Exclusive Global Deal
CompanyDeals

Merck Licenses SciBrunch’s Oral KRAS G12D Inhibitor SPR2015 in Up to USD 2.13 Billion Exclusive Global Deal

FDA Approves Eli Lilly's Olumiant for Pediatric Patients Aged 12 and Older With Severe Alopecia Areata
CompanyDrug

FDA Approves Eli Lilly’s Olumiant for Pediatric Patients Aged 12 and Older With Severe Alopecia Areata

FDA Approves Eli Lilly's Onswik – Once‑Weekly Basal Insulin for Adults With Type 2 Diabetes
CompanyDrug

FDA Approves Eli Lilly’s Onswik – Once‑Weekly Basal Insulin for Adults With Type 2 Diabetes

AstraZeneca to Invest USD 2 Billion in Summit Therapeutics – Clinical Collaboration Anchored on Ivonescimab and Claudin 18.2 ADC Sone‑Ve
CompanyDeals

AstraZeneca to Invest USD 2 Billion in Summit Therapeutics – Clinical Collaboration Anchored on Ivonescimab and Claudin 18.2 ADC Sone‑Ve

AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure
CompanyDrug

AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis
CompanyDrug

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis

CSPC's SYS6077 Wins NMPA Clinical Trial Approval – Off‑the‑Shelf Universal mRNA Cancer Vaccine for Advanced Malignant Tumors
CompanyDrug

CSPC’s SYS6077 Wins NMPA Clinical Trial Approval – Off‑the‑Shelf Universal mRNA Cancer Vaccine for Advanced Malignant Tumors

Novo Nordisk Licenses Hengrui's HRS‑1596 in Up to USD 2.6 Billion Global Deal – Once‑Weekly Oral Candidate for Obesity and Type 2 Diabetes
CompanyDeals

Novo Nordisk Licenses Hengrui’s HRS‑1596 in Up to USD 2.6 Billion Global Deal – Once‑Weekly Oral Candidate for Obesity and Type 2 Diabetes

Novo Nordisk Licenses Nanexa's PharmaShell Platform in Up to EUR 1.165 Billion Global Deal – Targeting Monthly and Quarterly Long‑Acting Injectables for Obesity and Type 2 Diabetes
CompanyDeals

Novo Nordisk Licenses Nanexa’s PharmaShell Platform in Up to EUR 1.165 Billion Global Deal – Targeting Monthly and Quarterly Long‑Acting Injectables for Obesity and Type 2 Diabetes

European Commission Revokes Hansoh's Aumolertinib Marketing Authorization – EU Approval Reversed Seven Months After Grant in TAGRISSO Data‑Protection Dispute
CompanyDrug

European Commission Revokes Hansoh’s Aumolertinib Marketing Authorization – EU Approval Reversed Seven Months After Grant in TAGRISSO Data‑Protection Dispute

Merck's Subcutaneous Pembrolizumab Approved by China's NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China
CompanyDrug

Merck’s Subcutaneous Pembrolizumab Approved by China’s NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China